Pacific Edge Limited

Last updated

Pacific Edge Limited
Company type Public
NZX: PEB
Industry Cancer diagnostics
Founded2001
Headquarters
Dunedin, New Zealand, and Hershey, USA
Area served
New Zealand, Australia, Spain, United States of America
Key people
David Darling [1] [2] (Group CEO) and Jackie Walker (CEO of Pacific Edge Diagnostics USA)
ProductsCxBladder Suite of bladder cancer diagnostics tools
Services Urology
Revenue$4m as at November 2015
Number of employees
Approx 50 globally
Website pacificedgedx.com

Pacific Edge Limited, based in New Zealand, focuses on cancer diagnostics with a suite of bladder cancer diagnostic tools using genetic biomarkers. The company operates with a head office in Dunedin, New Zealand, and also has an office in Hershey, USA. It is listed on the New Zealand NZX main board stock exchange and is included in the NZX 50 Index. [3]

Contents

History

Pacific Edge, founded in August 2001, [4] utilizes genetic biomarkers in urine for cancer detection. Their approach is positioned as cost-effective compared to other diagnostic methods. [5] The company offers diagnostic services in New Zealand and the United States and has partnerships in Europe and Australia.

Listed on the New Zealand NZX index, Pacific Edge has undertaken capital raising initiatives, with rounds in 2013 and 2015 aimed at advancing the commercialization of their diagnostic tests in the United States. [6] In June 2020, Pacific Edge secured a commercial relationship with Kaiser Permanente, one of the largest health insurance providers in the U.S., for its bladder cancer tests. [7]

Products

Pacific Edge offers a series of bladder cancer diagnostic tests known as CxBladder. These tests include specialist subtype products designed for the detection of cancerous cells and to aid clinicians and oncologists in triage. [8] The tests are based on non-invasive urine samples, utilizing RNA and protein assays. CxBladder is noted for its sensitivity and potential for earlier detection of bladder cancer, compared to other diagnostic methods such as cytology. [9] [10] [11] [12] [13] [14]

Awards

Pacific Edge has won a number of awards, including:

Related Research Articles

<span class="mw-page-title-main">SkyCity Entertainment Group</span> New Zealand gambling company

SkyCity Entertainment Group is a gambling and entertainment company based in Auckland, New Zealand. It owns and operates five casino properties in New Zealand and Australia, which include restaurants and bars, three hotels, a convention centre and Auckland's Sky Tower.

New Zealand's Exchange, known commonly as the NZX, is the national stock exchange for New Zealand and a publicly owned company. NZX is the parent company of Smartshares, and Wealth Technologies.

Graeme Richard Hart is a New Zealand billionaire businessman and the country's richest person. He prefers to stay out of the media and makes few public appearances. As of March 2022, his net worth was estimated at US$9.7 billion.

<span class="mw-page-title-main">Infratil</span> New Zealand investment company

Infratil Limited is a New Zealand–based infrastructure investment company. It owns renewable energy, digital infrastructure, airports, and healthcare assets with operations in New Zealand, Australia, Asia, the US and Europe. Infratil was founded by the late Lloyd Morrison, a Wellington-based merchant banker. Morrison's company, Morrison & Co is responsible for Infratil's management and administration.

<span class="mw-page-title-main">Lloyd Morrison</span>

Hugh Richmond Lloyd Morrison was a Wellington, New Zealand-based investment banker and entrepreneur. He founded H.R.L. Morrison & Co in 1988, and Morrison & Co launched the infrastructure company Infratil in 1994.

<span class="mw-page-title-main">Restaurant Brands</span> New Zealand fast food company

Restaurant Brands New Zealand Limited, trading as Restaurant Brands, is a New Zealand fast food company. Restaurant Brands currently operates and owns the master franchising rights for the Carl's Jr., KFC, Pizza Hut, and Taco Bell brands in New Zealand. Restaurant Brands operates most of New Zealand's stores for the brands they own rights to and provides management and support services to New Zealand's independent franchisees of the remaining stores.

<span class="mw-page-title-main">SLI Systems</span>

SLI Systems provided cloud-based search tools for online retailers under a "software as a service" (SaaS) model. It was a public company listed on the New Zealand stock exchange.

<span class="mw-page-title-main">EN2 (gene)</span> Protein-coding gene in the species Homo sapiens

Homeobox protein engrailed-2 is a protein that in humans is encoded by the EN2 gene. It is a member of the engrailed gene family.

<span class="mw-page-title-main">Windflow Technology</span> New Zealand wind energy company

Windflow Technology was a company based in Christchurch, New Zealand known for its unique wind turbine gearbox design and two-bladed turbines.

NMP22 is a tumor marker for bladder cancer. NMP22 is the abbreviated form of Nuclear Matrix Protein Number 22. It reflects the mitotic activity of cells.

<span class="mw-page-title-main">David Skegg</span> New Zealand epidemiologist (b. 1947)

Sir David Christopher Graham Skegg is a New Zealand epidemiologist and university administrator. He is an emeritus professor in the Department of Preventive and Social Medicine at the University of Otago. He was the vice-chancellor of the university from 2004 to 2011 and president of the Royal Society of New Zealand from 2012 to 2015. His primary research interest is cancer epidemiology.

A liquid biopsy, also known as fluid biopsy or fluid phase biopsy, is the sampling and analysis of non-solid biological tissue, primarily blood. Like traditional biopsy, this type of technique is mainly used as a diagnostic and monitoring tool for diseases such as cancer, with the added benefit of being largely non-invasive. Liquid biopsies may also be used to validate the efficiency of a cancer treatment drug by taking multiple samples in the span of a few weeks. The technology may also prove beneficial for patients after treatment to monitor relapse.

Vista Group International Limited is a multinational tech conglomerate that provides technology for film distribution, exhibition and analytics globally. They are made up of eight businesses with more than 630 staff across offices in Auckland, Sydney, Los Angeles, London, Shanghai, Beijing, Mexico City, South Africa, the Netherlands and Romania. Its software is installed in cinemas in 116 countries. Vista Group is listed on both the New Zealand Stock Exchange (NZX) and Australian Securities Exchange (ASX).

Metlifecare is one of New Zealand's largest retirement village providers. They currently own and operate 43 retirement villages throughout the North Island of New Zealand.

<span class="mw-page-title-main">Warren Tate</span> New Zealand biochemist and researcher

Warren Perry Tate is a New Zealand biochemist and professor of biochemistry at the University of Otago.

<span class="mw-page-title-main">Sealegs Amphibious Craft</span> Motor vehicle

Sealegs Amphibious Craft are a type of amphibious vehicle manufactured by Sealegs International Ltd, a company based in Auckland, New Zealand. Sealegs craft are aluminium fabricated boats fitted with either a hydraulic amphibious system or an electric amphibious system. Both amphibious systems consist of three wheels – one fitted to the bow and two fitted to the transom of the craft. In craft with the hydraulic system, these wheels are lifted, lowered and driven by the hydraulic system which is powered by a petrol engine mounted on the deck. In craft with the electric system, the wheels are equipped with brushless high-torque electric motors, and powered by a central 48-volt 7-kWh lithium battery pack.

Urinary cell-free DNA (ucfDNA) refers to DNA fragments in urine released by urogenital and non-urogenital cells. Shed cells on urogenital tract release high- or low-molecular-weight DNA fragments via apoptosis and necrosis, while circulating cell-free DNA (cfDNA) that passes through glomerular pores contributes to low-molecular-weight DNA. Most of the ucfDNA is low-molecular-weight DNA in the size of 150-250 base pairs. The detection of ucfDNA composition allows the quantification of cfDNA, circulating tumour DNA, and cell-free fetal DNA components. Many commercial kits and devices have been developed for ucfDNA isolation, quantification, and quality assessment.

<span class="mw-page-title-main">Serko</span> Travel management company

Serko Limited, known as Serko, is a travel management and expense technology company headquartered in New Zealand.

<span class="mw-page-title-main">Grant Baker (businessman)</span> New Zealand businessman and entrepreneur

Grant Baker is a New Zealand businessman, entrepreneur, and venture capitalist.

References

  1. "PEB.NZ Profile - Pacific Edge Limited Ordinary S Stock - Yahoo! Finance". Yahoo! Finance . Retrieved 31 December 2015.
  2. "Pacific Edge first-half loss widens". The New Zealand Herald . Retrieved 31 December 2015.
  3. "Pacific Edge Limited" . Retrieved 31 December 2015.
  4. "NZX Main Board - PEB Analysis". NZX . Retrieved 31 December 2015. Pacific Edge Limited (PEB) was formed in August 2001 following acquisition of intellectual property from the University of Otago.
  5. "Pacific Edge shares soar to new high". New Zealand Herald. 22 October 2013. ISSN   1170-0777 . Retrieved 31 December 2015.
  6. "Pacific Edge seeks $35.3M to fund US growth". The New Zealand Herald. Retrieved 31 December 2015.
  7. "Kaiser Permanente Approves Commercial Use of Cxbladder - NZX, New Zealand's Exchange". www.nzx.com. Retrieved 25 June 2020.
  8. "Suite of cancer products grows". Otago Daily Times. 29 December 2015. Retrieved 31 December 2015.
  9. Alan Wood (27 May 2015). "Pacific Edge's FY loss widens to $10.58m, plans to raise $35.3m". Stuff.co.nz . Retrieved 31 December 2015.
  10. Janis C. Kelly (26 October 2015). "Urinary Biomarkers Not Useful for Bladder Cancer Diagnosis". Medscape . Retrieved 31 December 2015.
  11. MARTA STEEMAN (9 June 2015). "Singapore hospital to trial Pacific Edge's main bladder cancer detection product". Stuff.co.nz . Retrieved 31 December 2015.
  12. "Warning over bladder cancer test". Stuff.co.nz . 11 July 2014. Retrieved 31 December 2015.
  13. "Pacific Edge sales up; still no profit". Otago Daily Times. 27 November 2015. Retrieved 31 December 2015.
  14. "Pacific Edge gets US approval for Dunedin laboratory". The New Zealand Herald . Retrieved 31 December 2015.